TriangleNCT02601209 · OUTCOME
Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD], and Progressive Disease [PD])(Phase II Analysis Group 2 - Initial Treatment Period)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 2 years
What was measured
The frequencies (and percentages) of tumor response categories (CR, PR, SD, PD) will be summarized for Phase II Analysis Group 2. Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion, b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. symptomatic deterioration. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD.
Analysis population: Phase II Analysis Group 2 - Initial Treatment Period; Patients with tumor response data available are included in this analysis.
Groups in this outcome
Phase II - Analysis Group 2 MLN0128
Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.
Phase II - Analysis Group 2 Pazopanib
Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.
| Group | Source count |
|---|---|
| Phase II - Analysis Group 2 MLN0128 | 44 |
| Phase II - Analysis Group 2 Pazopanib | 51 |
Reported measurements
Complete Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 | 0 | Not reported | Not reported | Not reported | Not reported |
| Phase II - Analysis Group 2 Pazopanib | 0 | Not reported | Not reported | Not reported | Not reported |
Partial Response
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 | 2 | Not reported | Not reported | Not reported | Not reported |
| Phase II - Analysis Group 2 Pazopanib | 2 | Not reported | Not reported | Not reported | Not reported |
Stable Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 | 14 | Not reported | Not reported | Not reported | Not reported |
| Phase II - Analysis Group 2 Pazopanib | 23 | Not reported | Not reported | Not reported | Not reported |
Progressive Disease
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase II - Analysis Group 2 MLN0128 | 28 | Not reported | Not reported | Not reported | Not reported |
| Phase II - Analysis Group 2 Pazopanib | 26 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- title
- Complete Response
- categories
- measurements
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 2
- title
- Partial Response
- categories
- measurements
- group Id
- OG000
- value
- 14
- group Id
- OG001
- value
- 23
- title
- Stable Disease
- categories
- measurements
- group Id
- OG000
- value
- 28
- group Id
- OG001
- value
- 26
- title
- Progressive Disease
- denoms
- counts
- group Id
- OG000
- value
- 44
- group Id
- OG001
- value
- 51
- units
- Participants
- description
- The frequencies (and percentages) of tumor response categories (CR, PR, SD, PD) will be summarized for Phase II Analysis Group 2. Complete Response (CR): All of the following must be true: a. Disappearance of all target lesions. b. Each target lymph node must have reduction in short axis to \< 1.0 cm. Partial Response (PR): At least a 30% decrease in PBSD taking as reference the BSD. Progression (PD): At least one of the following must be true: a. At least one new malignant lesion, b. At least a 20% increase in PBSD. c. PD via FDG-PET imaging. d. unequivocal progression of existing non-target lesions and non-target lymph nodes. e. symptomatic deterioration. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD.
- groups
- description
- Protocol therapy will consist of 30 mg MLN0128 (TAK-228) administered weekly over a 4-week cycle.
- id
- OG000
- title
- Phase II - Analysis Group 2 MLN0128
- description
- Patients receive 400mg Pazopanib orally once daily over a 4-week cycle and titrated to tolerance (maximum 800mg) by the treating physician in the first intervention period/initial treatment period.
- id
- OG001
- title
- Phase II - Analysis Group 2 Pazopanib
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Phase II Analysis Group 2 - Initial Treatment Period; Patients with tumor response data available are included in this analysis.
- reporting Status
- POSTED
- time Frame
- Up to 2 years
- title
- Tumor Response (Complete Response [CR], Partial Response [PR], Stable Disease [SD], and Progressive Disease [PD])(Phase II Analysis Group 2 - Initial Treatment Period)
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice